Automated cell culture systems have gained popularity for generating optimized cell lines across the entire spectrum ranging from seeding, feeding, passaging, to expansion of cells. They help meet strict standardization requirements, lowering contamination rates and minimizing human errors. Life sciences industries are harnessing automated systems for a wide spectrum of cell-based screening use in research and commercial applications. Demand in the automated cell culture systems market stems from the expanding the use of high-throughput cell lines in drug discovery research.
Automated cell culture helps in the production of large volumes and high-quality cell lines for drug research, rendering high safety and product efficacy. Other key research applications in the market are interference RNA (RNAi), cell-based drug transport, metabolism, and toxicology studies.
The report offers an in-depth insights into key growth dynamics, regulatory landscape, new avenues, and revenues in key applications. The assessments strive to take a closer look at the automation trends and key winning imperatives that may heavily influence the competitive dynamics in coming years.
Human pluripotent stem cell studies hold vast potential in modelling human diseases. Strides in the automated cell culture systems market have made this possible, and offer significant advantages over the manual ones. The growing popularity of personalized regenerative or cell replacement therapies is a key trend. Rapidly growing number of stem cell–based studies in developing and developed countries has imparted a robust fillip to the expansion in the automated cell culture systems market. Over the years, with personalized regenerative medicine gathering traction among life science research companies, new avenues have emerged.
Advances being made in structural biology have also spurred growth of the automated cell culture systems market.
Adoption of human iPSC lines in the generation of human iPSC lines has opened a new avenue in the automated cell culture systems market. They are benefitting from the development, manufacturing and customization of precision measurement devices. The generation of biobanks of iPSCs is a key trend in the automated cell culture systems market in developed regions, and is a key factor spurring industry collaborations of various types.
A case in point is when The California Institute for Regenerative Medicine (CIRM) collaborating with Cellular Dynamics International, Inc. (CDI) in the U.S. planned to generate 9000 iPSC lines from 3000 individuals. A number of consortiums have cropped up to this end. An example is The European Bank for induced pluripotent Stem Cells (EBiSC). Induced pluripotent stem cells cater to a wide range of diseases. Another example is the AUTOSTEM Consortium using automated cell culture systems for developing patient-specific iPSCs for ophthalmic research. Expanding the cell line in this manner will boost clinical trials for various diseases. Patients with ischemic strokes are likely to benefit from the clinical trials in Phase II from the adoption of automated cell culture system in CTX0E03 cell line.
Key industry players thriving in the automated cell culture systems market are Lonza Group Ltd., Merck KGaA, Promocell GmbH, and Hamilton Medical AG.
Regionally, North America has been presenting substantial revenue streams for manufacturers of automated cell culture systems. The healthcare system in developed parts of the region has seen personalized regenerative or cell replacement therapies gathering immense traction. Stakeholders in the region are leaning on the extensive application of automated stem cell culture in stem cell studies. The regional market has seen players constantly focusing on investing to expand the capacities of automated cell culture systems. The regional market has also benefitted from the increasing trend of modernization of stem cell biology.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Complete the form below and we'll get back to you shortly.